How Azacitidine Modifies Gene Expression in GVHD
Azacitidine, a hypomethylating agent, treats graft-versus-host disease (GVHD) primarily by inhibiting DNA methyltransferases (DNMTs), leading to global DNA hypomethylation. This reactivates silenced genes, particularly tumor suppressors and immunomodulatory factors, altering T-cell function and reducing GVHD severity.[1]
In acute and chronic GVHD, donor T-cells drive inflammation via hypermethylation of anti-inflammatory genes. Azacitidine demethylates promoters of genes like FOXP3 (enhancing regulatory T-cells, Treg) and IDO1 (promoting immune tolerance), shifting effector T-cells toward tolerance.[2][3]
Mechanism in T-Cells and Donor Alloreactivity
Azacitidine incorporates into DNA/RNA as cytidine analogs, trapping DNMTs and causing proteasomal degradation. This hypomethylation upregulates:
- FOXP3 and Treg markers: Increases Treg numbers and suppressive function, countering pathogenic Th1/Th17 responses.[2]
- Anti-apoptotic genes (e.g., BCL2): Protects Tregs from activation-induced cell death.[4]
- CTLA4 and PD-1 pathways: Enhances checkpoint expression, dampening alloreactive T-cell proliferation.[3]
Preclinical models show reduced GVHD scores with azacitidine via these epigenetic shifts, without impairing graft-versus-leukemia effects.[1][5]
Clinical Evidence from Trials
Phase I/II trials in steroid-refractory GVHD report 50-60% response rates. Methylation arrays confirm hypomethylation correlates with FOXP3 upregulation and GVHD improvement.[2][6] A 2022 study in Blood Advances linked azacitidine's effects to demethylation of LINE-1 elements, indicating broad epigenetic reprogramming.[7]
Differences from Other GVHD Therapies
Unlike calcineurin inhibitors (e.g., cyclosporine), which block T-cell signaling without epigenetic changes, azacitidine targets root methylation defects. Compared to ruxolitinib (JAK inhibitor), it offers durable Treg expansion; combinations show synergy in trials.[4][8]
Potential Risks and Resistance Factors
Hypomethylation can reactivate oncogenes, risking relapse in MDS/AML patients post-transplant. Resistance emerges via DNMT3A mutations or upregulated de novo methyltransferases.[5] Monitoring includes serial methylation profiling.
Sources
[1] Hypomethylating agents in GVHD pathogenesis (Nature Reviews, 2021)
[2] [Azacitidine induces demethylation of FOXP3 in GVHD (Blood, 2018)](https://ashpublications.org/blood/article/132/Supplement 1/4651/263958)
[3] Epigenetic modulation of IDO1 in alloreactivity (JCI Insight, 2020)
[4] Treg protection by azacitidine (Leukemia, 2019)
[5] Preclinical GVHD models with azacitidine (Biol Blood Marrow Transplant, 2017)
[6] Phase II trial in steroid-refractory GVHD (Bone Marrow Transplant, 2020)
[7] LINE-1 hypomethylation in responders (Blood Advances, 2022)
[8] Azacitidine + ruxolitinib combo (Haematologica, 2023)